Who funds gene therapy research?

We count 81 funded gene therapy projects, active between 2021 and 2031, from 6 funders. The most came from EU · ERC (30 projects), EU · MSCA (13 projects) and EU · EIC (10 projects). The median award is $2.4M, across the 79 of 81 projects that list an amount.

Funded projects

81

Funders

6

Median award

$2.4M

Open calls now

2

Top funders of gene therapy research

Projects whose title or summary mentions gene therapy. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open gene therapy funding calls

2 open calls mention gene therapy today.

• Cell and Gene Therapy for Personalised Medicine
  Research Council of NorwayNot specifiedDeadline: January 20, 2027 ·
• Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
  National Institutes of HealthNot specifiedDeadline: October 8, 2027 ·

Funded gene therapy projects

A sample, latest start first, at most three per program.

• CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
  NIH · Office of the Director · $6,277,391 · ends 2031
• Next Gen HSC GT for IEI: Developing the next generation of haematopoietic stem cell gene therapies for inborn errors of immunity
  UKRI · MRC · £459,532 · ends 2031
• Investigating the impact of pre-existing adenovirus immunity on the safety and efficacy of adenoviral-based vaccines and therapeutics
  Wellcome · £713,181 · ends 2030
• Collaborative Research: Multimodal Nanopore Biosensing and Nanosieving for Upstream Quality Control of AAV Gene Therapy Vectors
  NSF · ENG · $300,000 · ends 2029
• Enhanced gene editing strategies for the next generation of T cell therapies
  Wellcome · £1,187,300 · ends 2029
• Immunomodulation in AAV gene therapy
  NIH · NIAID · $3,192,404 · ends 2029
• Effective Delivery of Nucleic Acid Therapeutics via Designed Nanocarriers (NATPRIME)
  UKRI · Horizon Europe Guarantee · £267,922 · ends 2029
• Effective Delivery of Nucleic Acid Therapeutics via Designed Nanocarriers
  UKRI · Horizon Europe Guarantee · £267,922 · ends 2028
• Targeting adrenal stem cells by gene therapy to rescue adrenal insufficiency in Familial Glucocorticoid Deficiency type 2
  Wellcome · ends 2028
• Gene Therapy for APOE4 Homozygous Alzheimer's Disease
  NIH · NIA · $3,252,734 · ends 2028

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “gene therapy”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.